FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280534735> ?p ?o ?g. }

• W4280534735 endingPage "e513" @default.
• W4280534735 startingPage "e504" @default.
• W4280534735 abstract "A novel, engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX (FIX) protein (BBM-H901) has been developed and is promising for haemophilia B gene therapy. We aimed to explore its safety and activity in increasing FIX concentrations and reducing bleeding frequency.We did a single-centre, single-arm, phase 1, pilot trial evaluating the safety and activity of a single intravenous infusion of BBM-H901 at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Tianjin, China). We enrolled adult patients with haemophilia B (aged >18 years) with baseline FIX coagulation activity (FIX:C) of less than 2 IU/dL, no FIX inhibitor, and low titre of neutralising antibodies (≤1:4) against vector capsid. Eligible participants were intravenously infused with a single dose of 5 × 1012 vector genomes (vg)/kg of BBM-H901 after 1 week of prophylactic prednisone treatment (1 mg/kg per day). Primary endpoints were the incidence of treatment-related adverse events, change in alanine aminotransferase (ALT) and aspartate amino transferase (AST), and development of antibodies against vector capsid within 1 year of infusion. We report the results of the prespecified 1-year analysis following complete enrolment. The trial is registered with ClinicalTrials.gov, NCT04135300, and is complete.Between Oct 16, 2019, and Jan 13, 2021, 12 male participants were assessed, and ten Chinese participants were enrolled and infused with BBM-H901. After a median follow-up of 58 weeks (IQR 51·5-99·5), mean FIX:C reached mean 36·9 IU/dL (SD 20·5). No serious adverse events, no grade 3-4 adverse events were observed. Grade 1-2 adverse events related to BBM-H901 include pyrexia (1 [10%]) and elevation of aminotransferase(1 [10%]). No FIX inhibitors were observed. All participants developed antibodies against vector capsid after infusion. Eight (80%) participants had ALT and AST concentrations below the upper limit of normal throughout the follow-up period. Two (20%) participants had elevation of ALT and AST accompanied with decrease of FIX:C, which remained at 7 IU/dL and 11.8 IU/dL, respectively.This pilot study suggests that liver-tropic BBM-H901 is safe 1 year after infusion. Vector derived FIX:C concentration is sufficiently high to prevent bleeding events and minimise the need for replacement therapy in small populations with haemophilia B. These findings support further study.Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, National Key Research and Development Program of China, National Natural Science Foundation of China, Tianjin Municipal Science and Technology Commission Grant, and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences." @default.
• W4280534735 created "2022-05-22" @default.
• W4280534735 creator A5004859868 @default.
• W4280534735 creator A5009527477 @default.
• W4280534735 creator A5016701351 @default.
• W4280534735 creator A5018734313 @default.
• W4280534735 creator A5034537559 @default.
• W4280534735 creator A5039060782 @default.
• W4280534735 creator A5045714102 @default.
• W4280534735 creator A5047782155 @default.
• W4280534735 creator A5049542745 @default.
• W4280534735 creator A5054089629 @default.
• W4280534735 creator A5060867127 @default.
• W4280534735 creator A5062481811 @default.
• W4280534735 creator A5068777646 @default.
• W4280534735 creator A5070321359 @default.
• W4280534735 creator A5071037763 @default.
• W4280534735 creator A5071369567 @default.
• W4280534735 creator A5071580858 @default.
• W4280534735 creator A5071798264 @default.
• W4280534735 creator A5080945746 @default.
• W4280534735 creator A5083896582 @default.
• W4280534735 creator A5088938516 @default.
• W4280534735 creator A5089727554 @default.
• W4280534735 creator A5090056434 @default.
• W4280534735 creator A5090268948 @default.
• W4280534735 date "2022-07-01" @default.
• W4280534735 modified "2023-09-30" @default.
• W4280534735 title "Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial" @default.
• W4280534735 cites W1969271703 @default.
• W4280534735 cites W2055876243 @default.
• W4280534735 cites W2088410491 @default.
• W4280534735 cites W2122304523 @default.
• W4280534735 cites W2128915263 @default.
• W4280534735 cites W2167659424 @default.
• W4280534735 cites W2411144158 @default.
• W4280534735 cites W2587941297 @default.
• W4280534735 cites W2773253161 @default.
• W4280534735 cites W2773565340 @default.
• W4280534735 cites W2775538622 @default.
• W4280534735 cites W2982694372 @default.
• W4280534735 cites W3000219265 @default.
• W4280534735 cites W3047046471 @default.
• W4280534735 cites W3093323554 @default.
• W4280534735 cites W3204264938 @default.
• W4280534735 doi "https://doi.org/10.1016/s2352-3026(22)00113-2" @default.
• W4280534735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35598604" @default.
• W4280534735 hasPublicationYear "2022" @default.
• W4280534735 type Work @default.
• W4280534735 citedByCount "15" @default.
• W4280534735 countsByYear W42805347352022 @default.
• W4280534735 countsByYear W42805347352023 @default.
• W4280534735 crossrefType "journal-article" @default.
• W4280534735 hasAuthorship W4280534735A5004859868 @default.
• W4280534735 hasAuthorship W4280534735A5009527477 @default.
• W4280534735 hasAuthorship W4280534735A5016701351 @default.
• W4280534735 hasAuthorship W4280534735A5018734313 @default.
• W4280534735 hasAuthorship W4280534735A5034537559 @default.
• W4280534735 hasAuthorship W4280534735A5039060782 @default.
• W4280534735 hasAuthorship W4280534735A5045714102 @default.
• W4280534735 hasAuthorship W4280534735A5047782155 @default.
• W4280534735 hasAuthorship W4280534735A5049542745 @default.
• W4280534735 hasAuthorship W4280534735A5054089629 @default.
• W4280534735 hasAuthorship W4280534735A5060867127 @default.
• W4280534735 hasAuthorship W4280534735A5062481811 @default.
• W4280534735 hasAuthorship W4280534735A5068777646 @default.
• W4280534735 hasAuthorship W4280534735A5070321359 @default.
• W4280534735 hasAuthorship W4280534735A5071037763 @default.
• W4280534735 hasAuthorship W4280534735A5071369567 @default.
• W4280534735 hasAuthorship W4280534735A5071580858 @default.
• W4280534735 hasAuthorship W4280534735A5071798264 @default.
• W4280534735 hasAuthorship W4280534735A5080945746 @default.
• W4280534735 hasAuthorship W4280534735A5083896582 @default.
• W4280534735 hasAuthorship W4280534735A5088938516 @default.
• W4280534735 hasAuthorship W4280534735A5089727554 @default.
• W4280534735 hasAuthorship W4280534735A5090056434 @default.
• W4280534735 hasAuthorship W4280534735A5090268948 @default.
• W4280534735 hasConcept C120665830 @default.
• W4280534735 hasConcept C121332964 @default.
• W4280534735 hasConcept C126322002 @default.
• W4280534735 hasConcept C141071460 @default.
• W4280534735 hasConcept C194409129 @default.
• W4280534735 hasConcept C197934379 @default.
• W4280534735 hasConcept C2777081929 @default.
• W4280534735 hasConcept C2777232031 @default.
• W4280534735 hasConcept C2778385053 @default.
• W4280534735 hasConcept C2781221834 @default.
• W4280534735 hasConcept C61511704 @default.
• W4280534735 hasConcept C71924100 @default.
• W4280534735 hasConcept C90924648 @default.
• W4280534735 hasConceptScore W4280534735C120665830 @default.
• W4280534735 hasConceptScore W4280534735C121332964 @default.
• W4280534735 hasConceptScore W4280534735C126322002 @default.
• W4280534735 hasConceptScore W4280534735C141071460 @default.
• W4280534735 hasConceptScore W4280534735C194409129 @default.
• W4280534735 hasConceptScore W4280534735C197934379 @default.
• W4280534735 hasConceptScore W4280534735C2777081929 @default.
• W4280534735 hasConceptScore W4280534735C2777232031 @default.

• next